UNAIDS/10.03E / JC1767E (English original, March 2010) ISBN 978 92 9 173849 6
HIV drug resistance , Users Manual
December 2017
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Guidelines
June 2017
HIV strategic information for impact
Information Note
Advice for countries using or planning
to introduce dual HIV/syphilis RDT in antenatal services and other testing sites.
WHO/RHR/17.01
PLOS ONE | https://doi.org/10.1371/journal.pone.0192765 February 23, 2018
From choice, a world of possibilities
Want to change the world? Here's how...
"i asked: 'Why doesn't somebody do something?' Then I realized I was somebody"
Translating Community Research Into Global Policy Reform For National Action: A Checklist For Community Engagement To Implement The WHO Consolidated Guideline On The Sexual And Reproductive Health And Rights Of Women Living With HIV
3rd edition | December 2018
Policy
July 2012
Working Paper No. 3
Bull World Health Organ 2015;93:457–467 | doi: http://dx.doi.org/10.2471/BLT.14.147215
Accountability for the global health sector strategies, 2016–2021
WHO/CDS/HIV/19.7
Joint Action for Results
UNAIDS Outcome Framework: Business Case 2009–2011